When it comes to antithrombotic therapy in coronary artery disease, the central question is no longer "What should everyone get?" It's "What's right for this patient?"

In this episode, Drs. Heather Johnson, Ty Gluckman, and Davide Cappodano explore the modern balance between managing clotting and bleeding risk in patients on antiplatelets and anticoagulants. From the evolving role of aspirin and P2Y12 monotherapy to dual pathway inhibition and the management of CAD with atrial fibrillation, the conversation highlights a clear shift: less one-size-fits-all medicine, more individualized—and shared—decision-making.

Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine.

00:00 – Welcome & Introduction

03:57 – Is Aspirin Still King?

10:26 – Shorter DAPT, Earlier Monotherapy

14:09 – When More Is More: the COMPASS regimen

17:49 – When Less Is More: CAD + AF